ARTICLE | Finance

Ebb & Flow

February 22, 2010 8:00 AM UTC

The ability to manipulate the structure of protein therapeutics to improve them - almost to the degree that can be achieved with small molecules - is the vision for next-generation biologics company Eleven Biotherapeutics Inc.

Last week, Flagship Ventures and Third Rock Ventures committed $35 million in a tranched series A round. Third Rock's Mark Levin is a director and interim CEO...